恒生创新药ETF(159316)近5日净流入3.3亿元，最新规模再创新高，Pharma创新管线迎收获期

Group 1 - The Hang Seng Innovation Drug ETF (159316) has shown active trading with a turnover of 31.05% and a transaction volume of 499 million yuan as of August 25, 2025, indicating a strong market interest [1] - As of August 22, 2025, the latest scale of the Hang Seng Innovation Drug ETF reached 1.598 billion yuan, marking a new high since its inception [1] - In the past five trading days, the Hang Seng Innovation Drug ETF experienced net inflows on four occasions, totaling 330 million yuan [1] Group 2 - The Hang Seng Innovation Drug ETF closely tracks the Hang Seng Innovation Drug Index, which reflects the performance of Hong Kong-listed companies involved in the research, development, and production of innovative drugs [2] - The Hang Seng Hong Kong Stock Connect Innovation Drug Index (HSSCIHKI) is the only "100% purity" innovative drug index in the market, focusing on companies holding core patents and directly participating in innovative drug R&D and commercialization [2] - The Hang Seng Innovation Drug ETF (159316) is currently the only ETF product tracking the Hang Seng Innovation Drug Index, providing high elasticity and scarcity, thus helping investors seize the investment opportunities in the Hong Kong innovative drug sector [2] Group 3 - Domestic large pharmaceutical companies have stabilized their generic drug business after the impact of centralized procurement, and the results of their innovative transformation are significant [1] - Since 2025, Heng Rui Medicine has disclosed three BD collaborations with a total upfront payment of approximately 720 million USD, with potential total transaction amounts exceeding 13.7 billion USD, indicating that BD could become a sustainable income source [1] - China Biopharmaceutical announced in June that it would achieve a "landmark heavyweight external authorization transaction," and in July, it fully acquired Li Xin Pharmaceutical for a net amount of 500 million USD, enhancing its dual antibody/ADC platform and international R&D capabilities [1] - Recently, Heng Rui Medicine plans to repurchase up to 2 billion yuan, while Sheng Sen Pharmaceutical intends to repurchase up to 500 million yuan, demonstrating companies' confidence in future development through intensive buybacks and increases [1]